HGH Fragment 176-191vsNN1706

HGH Fragment 176-191 is the unmodified C-terminal segment of human growth hormone, representing exactly the last 16 amino acids of the 191-amino-acid GH molecule. Research identified this region as containing the molecular determinants responsible for GH's lipolytic activity, independent of the N-terminal domain that binds the growth hormone receptor and drives IGF-1 production and tissue growth.

The fragment activates lipolysis in white adipose tissue through interaction with beta-adrenergic signaling pathways. This triggers the cAMP/protein kinase A cascade that phosphorylates and activates hormone-sensitive lipase and perilipin proteins on the surface of lipid droplets within fat cells. The result is the breakdown of stored triglycerides into free fatty acids and glycerol, which are released into circulation for oxidation by energy-demanding tissues such as skeletal muscle and the liver.

Because the fragment lacks the binding regions for the GH receptor (located in amino acids 1-175), it does not activate the JAK2-STAT5 signaling pathway responsible for hepatic IGF-1 synthesis, somatic growth, or the insulin-antagonistic effects of full-length growth hormone. However, the shorter half-life compared to AOD-9604 (which has an additional stabilizing tyrosine residue) means more frequent dosing is required, and clinical evidence supporting its efficacy in humans remains very limited.

NN1706 is a once-daily GLP-1/GIP/glucagon triple receptor agonist — Novo Nordisk's mechanistic equivalent to Eli Lilly's retatrutide, designed to activate all three pathways simultaneously in a single molecule. Each receptor contributes complementary metabolic effects: GLP-1 agonism centrally suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion; GIP agonism augments insulin response and modulates adipose lipid handling; and glucagon receptor agonism in the liver drives fatty acid oxidation, ketogenesis, and hepatic glucose output, while in brown and beige adipose tissue it promotes thermogenesis and increases whole-body energy expenditure.

The key engineering challenge in any glucagon-containing multi-agonist is balancing glucagon's hyperglycemic tendency against the glucose-lowering effect of GLP-1 and GIP. NN1706's receptor potency ratios are tuned so that incretin-driven insulinotropic effects sufficiently offset glucagon-driven glucose production, producing net glycemic improvement alongside enhanced fat oxidation. The glucagon component is what differentiates triple agonists like NN1706 and retatrutide from dual GLP-1/GIP agonists like tirzepatide — the additional energy-expenditure and hepatic-fat-mobilising effects of glucagon are the main reason triple agonists have produced higher weight-loss numbers in early trials.

The pharmacokinetic profile gives NN1706 a half-life of roughly 14-18 hours, matched to once-daily subcutaneous dosing rather than the once-weekly schedule of retatrutide. The trade-off is more injections per week against tighter dose control, smoother plasma concentrations, and faster ability to adjust or pause dosing if side effects emerge. The first human data published in 2026 from Phase 1 trials in rodents, monkeys, and humans showed meaningful weight loss with an acceptable initial tolerability profile, setting up Phase 2 obesity and type 2 diabetes trials.